| Description of Property | Date Acquired | Cost or Other Basis | Prior Years' Depreciation | Computation Method | Rate / Life (# of years) |
Current Year's Depreciation Expense | Net Investment Income | Adjusted Net Income | Cost of Goods Sold Not Included |
|---|
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| ADICET BIO INC | 7,186 | 8,023 |
| ALIMERA SCIENCES INC | 293,663 | 230,834 |
| ALPINE IMMUNE SCIENCES | 533,261 | 1,819,982 |
| APEN PREFUNDED WARRANTS | 951,514 | 1,144,214 |
| APOLLO ENDOSURGERY | 1,354,686 | 2,644,965 |
| APPLIED THERAPEUTICS INC | 47,127 | 55,025 |
| ARDELYX INC | 1,050,338 | 1,146,005 |
| ATHIRA PHARMA ORD SHS | 343,597 | 609,650 |
| BIODELIVERY SCIENCES INTERNATI | 282,794 | 298,200 |
| CATALYST BIOSCIENCES INC | 144,732 | 204,513 |
| CIDARA THERAPEUTICS INC | 80,987 | 50,000 |
| CODA OCTOPUS GROUP, INC | 157,642 | 172,377 |
| CRINETICS PHARMACEUTICALS INC | 86,531 | 91,715 |
| CTI BIOPHARMA CORPORATION | 3,066 | 9,660 |
| CYREN LTD | 32,688 | 34,618 |
| DIAMEDICA THERAPEUTICS INC | 335,012 | 639,368 |
| HTG MOLECULAR DIAGNOSTICS CNV | 400,020 | 216,508 |
| HTG MOLECULAR DIAGNOSTICS INC | 207,953 | 233,235 |
| ICAD INC. | 324,175 | 477,259 |
| LIQTECH INTERNATIONAL INC | 2,086,059 | 3,503,008 |
| LIQTECT INTERNATION INC - CERT | 2,575,001 | 2,575,000 |
| MISONIX INC | 145,351 | 112,500 |
| MOLECULAR TEMPLATES INC | 375,890 | 362,492 |
| NEOS THERAPEUTICS INC | 324,845 | 170,090 |
| ORYZON GENOMICS | 97,644 | 121,736 |
| OTONOMY INC | 302,905 | 773,152 |
| PIXELWORKS, INC | 216,396 | 245,340 |
| PLUG POWER INC | 2,930 | 33,910 |
| POLARITYTE INC | 30,625 | 2,040 |
| QUICKLOGIC | 11,697 | 15,160 |
| RECRO PHARMA INC | 190 | 285 |
| REPRO MEDSYSTEMS INC | 116,665 | 180,600 |
| STEMLINE THERAPEUTICS, INC. RI | 42,990 | 42,979 |
| SUNESIS PHARMACEUTICALS INC | 495,149 | 541,618 |
| URANIUM ENERGY CORP COM | 64,658 | 105,600 |
| UROGEN PHARMA LTD | 190,245 | 168,541 |
| VERTTEX ENERGY, INC | 473,145 | 337,283 |
| VINCERA PHARMA INC | 107,228 | 240,465 |
| VINCERA PHARMA INC WTS.EXP 12/ | 22,852 | 81,510 |
| X4 PHARMACEUTICALS | 507,113 | 463,487 |
| Category/ Item | Listed at Cost or FMV | Book Value | End of Year Fair Market Value |
|---|---|---|---|
| GAIN THERAPEUTICS, INC SER B | 749,999 | 749,999 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| Administrative Fees | 47,173 | 47,173 | ||
| Bank Charges | 9 | 9 | ||
| State or Local Filing Fees | 25 | 25 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| Interest Income from Notes | 28,750 | 28,750 |
| Borrower's Name | Relationship to Insider | Original Amount of Loan | Balance Due | Date of Note | Maturity Date | Repayment Terms | Interest Rate | Security Provided by Borrower | Purpose of Loan | Description of Lender Consideration | Consideration FMV |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CYREN LTD | 1,000,000 | 1,000,000 | 2020-03 | 2024-03 | INTEREST/PRINCIPAL DUE SEMI-ANNUALLY & ON MATURITY | 575 % | NONE | INVESTMENT | CASH | 1,000,000 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| 990-PF Estimated Tax for 2020 | 74,800 | |||
| 990-PF Excise Tax for 2019 | 8,566 |